Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Stocks Under $10 to Buy and Hold Forever. On March 27, Nuvation Bio Inc. (NYSE:NUVB) and Eisai announced that the European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA) for Taletrectinib, which is marketed as IBTROZI in the US and Japan.

​Taletrectinib targets advanced ROS1-positive non-small cell lung cancer. Management noted that they expect a standard review timeline. This builds on the earlier January 2026 exclusive licensing deal between Eisai and Nuvation Bio for Europe and select regions outside the US, China, and Japan.

​Management noted that Europe sees around 400,000 annual lung cancer diagnoses, out of which non-small cell lung cancer comprises 80% of the cases and more than 2% advanced ROS1-positive cases. This translates to roughly 6,400 patients a year. Taletrectinib is a highly selective oral ROS1 inhibitor with a strong efficacy and safety profile, positioning it as a potential standard-of-care.

​Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company developing new treatments for difficult-to-treat cancers. The company was founded by David Hung in 2018, and its headquarters are in New York City.

While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.